IRVINE, Calif., June 16, 2026
Allergan Aesthetics, an AbbVie company, has received U.S. Food and Drug Administration (FDA) approval for SKINVIVE by JUVÉDERM® for the treatment of horizontal neck lines and improvement of neck appearance in adults aged 21 years and older. The milestone makes SKINVIVE the first and only hyaluronic acid injectable approved in the United States for reducing neck lines, including those commonly associated with prolonged use of digital devices, often referred to as “tech-neck.” The approval represents the second FDA-approved indication for SKINVIVE, which was initially approved in 2023 to improve cheek skin smoothness. With growing consumer demand for non-surgical aesthetic treatments targeting the neck and lower face, the new indication significantly expands treatment options available to aesthetic providers and patients seeking minimally invasive solutions for visible signs of aging and skin quality concerns.
Pivotal Clinical Study Demonstrates Significant Improvement in Neck Lines
The FDA approval was supported by results from a randomized, multicenter, evaluator-blinded, controlled pivotal clinical study that evaluated the safety and effectiveness of SKINVIVE by JUVÉDERM® in improving horizontal neck wrinkles. Study findings demonstrated that 74.8% of treated participants achieved clinically significant improvement of at least one grade on the validated Allergan Transverse Neck Lines Scale one month after treatment. Furthermore, the durability of response remained notable throughout the study period, with approximately 66% of participants maintaining improvement at six months following treatment.
Investigators also reported that more than 78% of participants maintained improvement from baseline across all evaluation timepoints, underscoring the product’s sustained aesthetic benefits. The injectable formulation works by helping skin retain its natural moisture, softness, and smoothness, resulting in a visible reduction in horizontal neck lines while enhancing overall neck appearance. Treatment is administered using an ultrafine needle or cannula and contains a small amount of lidocaine to improve patient comfort during the procedure. Results can last up to six months when optimal treatment protocols are followed.
Expanding Science-Driven Innovation in Medical Aesthetics
Advertisement
The approval further strengthens Allergan Aesthetics’ leadership position in the rapidly evolving medical aesthetics market. Company executives highlighted the growing need for scientifically validated treatments addressing aesthetic concerns beyond traditional facial indications. Neck aging has become an increasingly important area of focus due to factors such as natural aging, sun exposure, weight fluctuations, and the widespread use of smartphones, tablets, and digital devices that contribute to repetitive downward head positioning.
SKINVIVE’s newly approved indication provides aesthetic practitioners with a differentiated treatment option designed specifically for neck skin quality improvement. According to Allergan Aesthetics, the product will be supported by a dedicated provider training program required by the FDA before purchase and administration, helping ensure safe and effective clinical use. The company expects broad commercial availability later this year, further expanding access to advanced injectable treatments within the aesthetics sector.
Safety Profile Supports Broader Clinical Adoption
Clinical safety findings were consistent with the established profile of hyaluronic acid injectable treatments. The most commonly reported adverse events included redness, bruising, tenderness, swelling, firmness, itching, discoloration, and temporary lumps or bumps at the injection site. Most reactions were mild, required no treatment, and resolved within two weeks. Severe adverse events occurred in fewer than five percent of participants reporting treatment-related events.
The favorable safety profile, combined with meaningful efficacy outcomes and minimal downtime, positions SKINVIVE as an important addition to the growing portfolio of minimally invasive aesthetic procedures. As patient demand continues to rise for non-surgical cosmetic enhancements that deliver natural-looking results with limited recovery time, the FDA approval of SKINVIVE for neck rejuvenation represents a significant advancement in evidence-based aesthetic medicine and reinforces Allergan Aesthetics’ commitment to innovation in injectable therapies.
Source: AbbVie press release
